The global Herpes Simplex Virus treatment market size was valued at USD 2.93 billion in 2025 and is expected to reach USD 4.63 billion by 2033, at a CAGR of 5.90% during the forecast period
The market growth is largely fueled by the rising global prevalence of HSV-1 and HSV-2 infections, increasing diagnosis rates, and expanding awareness regarding long-term antiviral therapy, which is driving greater treatment demand across both developed and emerging regions
Furthermore, advancements in antiviral drug development, growing interest in novel therapies, and wider accessibility through hospital, retail, and online pharmacies are strengthening the treatment landscape. These converging factors are accelerating the adoption of HSV management solutions, thereby significantly boosting the industry's overall growth